A5080065227- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Occupational and environmental lung diseases
- CAR-T cell therapy research
- Extracellular vesicles in disease
- Pleural and Pulmonary Diseases
- Cancer-related molecular mechanisms research
- Meningioma and schwannoma management
- Cancer-related Molecular Pathways
- Advanced Breast Cancer Therapies
- Glioma Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Ovarian cancer diagnosis and treatment
- Folate and B Vitamins Research
- Frailty in Older Adults
- Metastasis and carcinoma case studies
- Neonatal Health and Biochemistry
- PARP inhibition in cancer therapy
- Nosocomial Infections in ICU
- Hepatitis B Virus Studies
- Exercise and Physiological Responses
- Brain Metastases and Treatment
Fiona Stanley Hospital
2025
Loxo Oncology at Lilly (United States)
2023
Salk Institute for Biological Studies
2022
Sir Charles Gairdner Hospital
2017-2021
The University of Western Australia
2019-2020
ACT Government
2018
Canberra Hospital
2010-2018
European Institute of Oncology
2018
Université Libre de Bruxelles
2018
Institut Jules Bordet
2018
Immune checkpoint inhibitors have changed the landscape of treatment multiple solid malignancies, and been used increasingly in recent years. Although usually well tolerated, given relative inexperience using immune inhibitors, we are still learning new side effects from treatment. We report on two cases ocular myasthenia gravis that occurred after with pembrolizumab, an antiprogrammed-death (anti-PD1) monoclonal antibody for advanced melanoma responding patients. One case is 81-year-old man...
Abstract The combination of ipilimumab and nivolumab is a highly active systemic therapy for metastatic melanoma but can cause significant toxicity. We explore the safety efficacy this treatment in routine clinical practice, particularly setting serine/threonine‐protein kinase B‐Raf (BRAF)‐targeted therapy. Consecutive patients with unresectable stage IIIC/IV commenced on across 10 tertiary institutions Australia were identified retrospectively. Data collected included demographics, response...
This study compares the detection sensitivity of two separate liquid biopsy sources, cell-free (cf) DNA/RNA and extracellular vesicle (EV)-associated (EV-DNA/RNA), to identify circulating Human Papilloma Virus (HPV) in plasma obtained from patients with oropharyngeal squamous cell carcinoma (OPCSCC). We also report on longitudinal changes observed HPV-DNA levels response treatment.A prospective was conducted that included 22 locally advanced disease six metastatic OPCSCC. Twenty-three had...
Abstract Aim There is currently a need to identify prognostic biomarkers assist in risk adopted approach treatment of malignant pleural mesothelioma (MPM). Expression programmed death ligand 1 (PD‐L1) has been studied as biomarker number tumors given its central role antitumoral immune response evasion. Four previously published analyses found PD‐L1 positivity be an adverse survival factor MPM. This study aims further investigate the relationship between expression tissues and outcome....
ANZ Journal of SurgeryEarly View IMAGES FOR SURGEONS Combination Lenvatinib and pembrolizumab as neoadjuvant treatment for BRAF negative anaplastic thyroid cancer Zhao Jie BMed/MD, MS, MS orcid.org/0000-0002-9766-991X Endocrine Surgery, Fiona Stanley Hospital, Perth, Western Australia, AustraliaSearch more papers by this authorBella Nguyen MBBS, FRACP, Bella FRACP Australia Contribution: Conceptualization, Writing - review & editingSearch authorDean Lisewski BSc (Hons1), MB BS, FRCSI, FRACS,...
There is limited real-world data on the efficacy and safety of combination programmed cell death protein-1 (PD-1) inhibitor, nivolumab cytotoxic T-lymphocyte antigen (CTLA-4) inhibitor ipilimumab.We retrospectively identified patients (pts) with metastatic melanoma treated three-weekly (1 mg/kg) in ipilimumab (3 for four cycles followed by monotherapy fortnightly. Patient demographics treatment parameters were collected outcomes determined.A total 45 pts received a median follow up 8.7...
There is increasing recognition of circulating tumour DNA (ctDNA) as a non-invasive alternative to tissue for the molecular characterisation and monitoring disease. Recent evidence suggests that cancer-associated changes can also be detected in contained within extracellular vesicles (EVs). As yet, there has been limited investigation into relationship between EV ctDNA, no studies have examined breast cancer patients. The aim this study was use low-pass whole-genome sequencing identify copy...
Pleural effusion (PE) is a common feature of malignant pleural mesothelioma. These effusions typically contain lymphocytes and cells. We postulated that the PE would be source for analysis tumor immune milieu. The aim this study was to compare phenotype T cell receptor usage cells with paired concurrently drawn peripheral blood lymphocytes. used multi-parameter flow cytometry high-throughput sequencing analyse mononuclear Both CD8+ CD4+ from showed increased expression inhibitory receptors...
Every year, about 1800 Australians die of hepatocellular carcinoma (HCC), the most common type primary liver cancer.1 Aboriginal and Torres Strait Islander peoples Australia (hereon respectfully referred to as First Nations Australians) are 2.5 times more likely develop HCC 1.4 from than non-Indigenous Australians.2 with have a 9% five-year survival rate compared 23% for Australians,2 half be diagnosed early-stage receive curative therapy.2 This is driven by being adversely affected social,...
In response to growing concern of an iodine deficiency emergence in Australia, this study was conducted document the status pregnant women ACT. One hundred presenting antenatal clinic at The Canberra Hospital answered a brief dietary questionnaire and provided spot urine sample for measurement excretion. results revealed that majority were consuming diet low iodine, confirmed by suboptimal concentrations their urine.
Abstract Low-coverage whole-genome sequencing (LC-WGS) can provide insight into oncogenic molecular changes. Serum extracellular vesicles (EV) represent a novel liquid biopsy source of tumoral DNA. This study compared copy number alteration (CNA) profiles generated from LC-WGS formalin-fixed paraffin-embedded (FFPE) DNA and EV-DNA obtained cancer patients. Patients with squamous cell carcinoma the base tongue (n = 3) cutaneous 2) were included. (0.5-1X coverage) was performed on FFPE-DNA...
Abstract Aim To examine the current patterns of end‐of‐life care medical oncology patients dying in an Australian tertiary acute hospital setting order to determine potential areas for improvement. Methods A retrospective observational study was undertaken 295 consecutive adult inpatients between 2010 and 2015. Charts were reviewed evidence (1) resuscitation plans, (2) interventions 48‐h period prior death, (3) palliative involvement (4) recognition patient comfort plans. Results At time 98%...
The EMBER trial (NCT04188548) demonstrated that the next generation oral SERD, imlunestrant, had favourable safety and pharmacokinetics profiles with a clinical benefit rate (CBR) of 42% in 114 patients (pts) ER+, HER2- aBC. Here we explore association between ctDNA results at baseline CBR pts treated imlunestrant. Baseline plasma samples from aBC single agent imlunestrant (at doses ranging 200-1200 mg QD) were sequenced using Guardant360 assay. positivity alterations (CR or PR, stable...
Shahnam, Adel MChD*; Paver, Elizabeth MBBS†; Nguyen, Bella MBBS*; Fadia, Mitali MD†; Ali, Sayed MBBS* Author Information